Causal effect of gut microbiota and its metabolites on cerebral small vessel disease: A multivariable Mendelian

Hao Xue1, Jing Zang, Fang Yang

  • 1Department of Neurology (No. 2), People's Hospital of Rizhao, Rizhao, Shandong Province, China.

Medicine
|December 16, 2025
PubMed

Insights

Cerebral small vessel disease (CSVD) is causally linked to gut microbiota (GM) and their metabolites. This study identifies specific gut bacteria and metabolites influencing CSVD risk, offering new therapeutic targets.

Area of Science:

  • Neuroscience
  • Microbiology
  • Genetics

Background:

  • Cerebral small vessel disease (CSVD) encompasses lacunar stroke, microbleeds, perivascular spaces (PVSs), and white matter hyperintensity (WMH).
  • A strong association exists between CSVD, gut microbiota (GM), and their metabolites, but causality is unproven.

Purpose of the Study:

  • To investigate the potential causal relationships between CSVD subtypes, GM, and gut microbiota-derived metabolites (GMDMs).
  • To identify specific gut bacteria and GMDMs that may serve as biomarkers or therapeutic targets for CSVD.

Main Methods:

  • A 2-sample Mendelian randomization (MR) analysis utilizing genome-wide association study data.
  • Employed various MR methods (IVW, weighted median, MR-Egger, MR-PRESSO) and sensitivity analyses to assess causality and pleiotropy.
  • Conducted enrichment analyses to explore underlying biological pathways.

Main Results:

  • Identified causal links between specific GM features and CSVD subtypes, with some bacteria increasing and others decreasing risk.
  • Established a potential causal association between 28 GMDMs and CSVD.
  • Enrichment analyses highlighted key regulatory pathways involved in the GM-CSVD axis.

Conclusions:

  • Provides evidence for a causal relationship between GM, GMDMs, and CSVD.
  • Suggests that gut microbiota and their metabolites are potential biomarkers and therapeutic targets for managing CSVD.

Related Concept Videos

Introduction to the Human Microbiota01:22

Introduction to the Human Microbiota

Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity, and disease...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Gut-Brain Axis01:22

Gut-Brain Axis

The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...